Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine …
M Pérol, C Chouaid, D Pérol, F Barlési… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This phase III study investigated whether continuation maintenance with
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III …
T Brodowicz, M Krzakowski, M Zwitter, V Tzekova… - Lung cancer, 2006 - Elsevier
PURPOSE: The primary objective of this randomized phase III study was to show significant
difference in median time to progression (TTP) in patients with advanced NSCLC treated …
difference in median time to progression (TTP) in patients with advanced NSCLC treated …
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G …
CP Belani, DM Waterhouse, H Ghazal… - Journal of Clinical …, 2010 - ascopubs.org
7506 Background: The use of single agent cytotoxic or targeted agent as maintenance
following combination therapyrepresents a useful strategy to improve patient outcomes in …
following combination therapyrepresents a useful strategy to improve patient outcomes in …
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by …
C Gridelli, F Ciardiello, R Feld, CA Butts… - Journal of Clinical …, 2010 - ascopubs.org
7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer
PM Fidias, SR Dakhil, AP Lyss, DM Loesch… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced
non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line …
non–small-cell lung cancer (NSCLC). For patients without progression, timing of second-line …
Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin …
JF Vansteenkiste, JE Vandebroek, KL Nackaerts… - Annals of oncology, 2001 - Elsevier
Background The modest improvement in median survival of advanced non-small-cell lung
cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical …
cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical …
Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in …
M Perol, C Chouaid, BJ Milleron, R Gervais… - Journal of Clinical …, 2010 - ascopubs.org
7507 Background: NSCLC patients (pts) whose tumors have not progressed following
platinum-based chemotherapy (CT) obtain PFS and OS benefits with maintenance CT or …
platinum-based chemotherapy (CT) obtain PFS and OS benefits with maintenance CT or …
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer
GV Scagliotti, P Parikh, J Von Pawel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …
相关搜索
- either gemcitabine induction chemotherapy
- erlotinib maintenance therapy
- cisplatin gemcitabine lung cancer
- ifct gfpc induction chemotherapy
- lung cancer randomized phase
- lung cancer pemetrexed and gemcitabine
- lung cancer delayed docetaxel
- lung cancer docetaxel consolidation
- lung cancer maintenance gefitinib
- lung cancer concurrent chemoradiotherapy
- cisplatin gemcitabine induction chemotherapy
- lung cancer induction chemotherapy
- cisplatin gemcitabine ifct gfpc
- pemetrexed and gemcitabine randomized phase
- lung cancer prolonged therapy
- maintenance gefitinib docetaxel consolidation